Current challenges and opportunities for bacillus Calmette-Guérin replacement vaccine candidates

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations

Abstract

Bacillus Calmette-Guérin (BCG) remains the only licensed vaccine against human tuberculosis (TB). BCG is a live-attenuated strain of Mycobacterium bovis, with limitations in efficacy against respiratory TB, the most common form of the disease responsible for transmission. However, continues to be used in the immunization programmes of different countries in the absence of another alternative. In order to improve BCG efficacy against pulmonary TB, in the current clinical TB vaccine pipeline, there are live-attenuated TB vaccines to replace BCG. This review discusses the current status of the development of live vaccine candidates designed to replace BCG from the rational strategies and immunological challenges to its clinical trial and identify key areas in the next years considered essential to confer improved safety and efficacy over BCG.

Original languageEnglish
Article numbere12772
JournalScandinavian Journal of Immunology
Volume90
Issue number4
DOIs
StatePublished - 1 Oct 2019

Keywords

  • bacillus Calmette-Guérin
  • immune response
  • infection
  • tuberculosis
  • vaccines

Fingerprint

Dive into the research topics of 'Current challenges and opportunities for bacillus Calmette-Guérin replacement vaccine candidates'. Together they form a unique fingerprint.

Cite this